A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma

Clinical trial NCT04337931 · TERMINATED

Trial details

NCT number: NCT04337931
Sponsor: Apexigen America, Inc.
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Unresectable Melanoma Metastatic Melanoma Cancer Cancer of Skin Melanoma Melanoma (Skin)

Start date: 2019-06-12
Primary completion: 2022-07-29
Enrollment: 45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.